Previous Close | 89.22 |
1-Year Change | 0% |
6-Months Change | -6.8% |
3-Months Change | 19.2% |
Moving Avg (50d) | 77.548 |
Moving Avg (200d) | 81.782 |
ESG Rating | - |
Exchange | NYSE |
Market Cap. | 4.53B |
Beta (3-Years) | 0.81 |
Revenue Growth (ttm) | 49.97% |
Net Profit Margin (ttm) | 10.35% |
Return On Assets (ttm) | 6.38% |
EPS (ttm) | 2.49 |
PE Ratio (ttm) | 35.83 |
Dividend Yield | % |
Asset Description: | Haemonetics Corporation |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2024-10-29 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
87.261 | 89.828 | 91.539 | 94.105 | 98.383 | 102.66 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.